Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)

American Journal of Cardiology

Volumn 105, Issue 4, 2010, Pages 445-452

  Cannon, Christopher P ^a   Rhee, Karen E ^b   Califf, Robert M ^c   Boden, William E ^d   Hirsch, Alan T ^e   Alberts, Mark J ^f   Cable, Greg ^g   Shao, Mingyuan ^h   Ohman, E Magnus ⁱ   Steg, P Gabriel ^j   Eagle, Kim A ^k   Bhatt, Deepak L ^l  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MIRIAM HOSPITAL   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g sanofi aventis ^*  (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k UNIVERSITY OF MICHIGAN   (United States)

^l VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ARTICLE; ATHEROTHROMBOSIS; CARDIOLOGIST; CAUCASIAN; DIABETES MELLITUS; DRUG MEGADOSE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; RISK ASSESSMENT; SECONDARY PREVENTION; SEX DIFFERENCE; SMOKING; THROMBOSIS; UNITED STATES; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ASPIRIN; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; WORLD HEALTH;

EID: 75349099088     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.10.014     Document Type: Article

References (18)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
2. Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Baggish J.S., Bhatt D.L., and Topol E.J. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 95 (2005) 1218-1222
3. Smith Jr. S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., Grundy S.M., Hiratzka L., Jones D., Krumholz H.M., Mosca L., Pasternak R.C., Pearson T., Pfeffer M.A., and Taubert K.A. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
4. Bhatt D.L., Steg P.G., Ohman E.M., Hirsch A.T., Ikeda Y., Mas J.L., Goto S., Liau C.S., Richard A.J., Rother J., and Wilson P.W. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295 (2006) 180-189
5. Steg P.G., Bhatt D.L., Wilson P.W., D'Agostino Sr. R., Ohman E.M., Rother J., Liau C.S., Hirsch A.T., Mas J.L., Ikeda Y., Pencina M.J., and Goto S. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297 (2007) 1197-1206
6. Ohman E.M., Bhatt D.L., Steg P.G., Goto S., Hirsch A.T., Liau C.S., Mas J.L., Richard A.J., Rother J., and Wilson P.W. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 151 (2006) 786.e1-786.e10
7. Vandenbroucke J.P., von Elm E., Altman D.G., Gotzsche P.C., Mulrow C.D., Pocock S.J., Poole C., Schlesselman J.J., and Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 147 (2007) W163-W194
8. Newby L.K., LaPointe N.M., Chen A.Y., Kramer J.M., Hammill B.G., DeLong E.R., Muhlbaier L.H., and Califf R.M. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113 (2006) 203-212
9. Algra A., De Schryver E.L., van Gijn J., Kappelle L.J., and Koudstaal P.J. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 3 (2006) CD001342
10. Anand S., Yusuf S., Xie C., Pogue J., Eikelboom J., Budaj A., Sussex B., Liu L., Guzman R., Cina C., Crowell R., Keltai M., and Gosselin G. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357 (2007) 217-227
11. Hurlen M., Abdelnoor M., Smith P., Erikssen J., and Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347 (2002) 969-974
12. Manzano-Fernández S., Pastor F.J., Marín F., Cambronero F., Caro C., Pascual-Figal D.A., Garrido I.P., Pinar E., Valdés M., and Lip G.Y. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 134 (2008) 559-567
13. Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., Buring J., Hennekens C., Kearney P., Meade T., Patrono C., Roncaglioni M.C., and Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009) 1849-1860
14. Wolff T., Miller T., and Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 150 (2009) 405-410
15. Belch J., MacCuish A., Campbell I., Cobbe S., Taylor R., Prescott R., Lee R., Bancroft J., MacEwan S., Shepherd J., Macfarlane P., Morris A., Jung R., Kelly C., Connacher A., Peden N., Jamieson A., Matthews D., Leese G., McKnight J., O'Brien I., Semple C., Petrie J., Gordon D., Pringle S., and MacWalter R. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337 (2008) a1840
16. Fowkes FGR, Price JF, Stewart MCW, Butcher I, Leng GC, Pell ACH, Sandercock PAG, Fox KAA, Lowe GDO, Murray GD; Aspirin for Asymptomatic Atherosclerosis Trialists. Randomised controlled trial of low dose aspirin in the prevention of cardiovascular events and death in subjects with asymptomatic atherosclerosis. Presented at the European Society of Cardiology, Barcelona, Spain, 2009.
17. Ogawa H., Nakayama M., Morimoto T., Uemura S., Kanauchi M., Doi N., Jinnouchi H., Sugiyama S., and Saito Y. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300 (2008) 2134-2141
18. Berger J.S., Krantz M.J., Kittelson J.M., and Hiatt W.R. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 301 (2009) 1909-1919